| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Molecular and Cellular Biology Research, Sunnybrook and Women’s College Health Sciences Centre, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 2 Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; 3 Department of Surgery, St. Jude Children’s Research Hospital, Memphis, Tennessee; and 4 ImClone Systems, Inc., New York, New York
A major obstacle compromising the successful application of many of the new targeted anticancer drugs, including angiogenesis inhibitors, is the empiricism associated with determining an effective biological/therapeutic dose because many of these drugs express optimum therapeutic activity below the maximum tolerated dose, if such a dose can be defined. Hence, surrogate markers are needed to help determine optimal dosing. Here we describe such a molecular marker, increased plasma levels of vascular endothelial growth factor (VEGF), in normal or tumor-bearing mice that received injections of an anti-VEGF receptor (VEGFR)-2 monoclonal antibody, such as DC101. Rapid increases of mouse VEGF (e.g., within 24 hours) up to 1 order of magnitude were observed after single injections of DC101 in non–tumor-bearing severe combined immunodeficient or nude mice; similar increases in human plasma VEGF were detected in human tumor-bearing mice. RAFL-1, another anti-VEGFR-2 antibody, also caused a significant increase in plasma VEGF. In contrast, increases in mouse VEGF levels were not seen when small molecule VEGFR-2 inhibitors were tested in normal mice. Most importantly, the increases in plasma VEGF were induced in a dose-dependent manner, with the maximum values peaking when doses previously determined to be optimally therapeutic were used. Plasma VEGF should be considered as a possible surrogate pharmacodynamic marker for determining the optimal biological dose of antibody drugs that block VEGFR-2 (KDR) activity in a clinical setting.
This article has been cited by other articles:
|
|
 |
|
  S. Jain, G. Chakraborty, R. Raja, S. Kale, and G. C. Kundu Prostaglandin E2 Regulates Tumor Angiogenesis in Prostate Cancer Cancer Res., October 1, 2008; 68(19): 7750 - 7759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kerbel Tumor Angiogenesis N. Engl. J. Med., May 8, 2008; 358(19): 2039 - 2049. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sarker, R. Molife, T.R. J. Evans, M. Hardie, C. Marriott, P. Butzberger-Zimmerli, R. Morrison, J. A. Fox, C. Heise, S. Louie, et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2008; 14(7): 2075 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Beaudry, M. Nilsson, M. Rioth, D. Prox, D. Poon, L. Xu, P. Zweidler-Mckay, A. Ryan, J. Folkman, S. Ryeom, et al. Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium Mol. Cancer Ther., February 1, 2008; 7(2): 418 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, et al. Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade PNAS, November 20, 2007; 104(47): 18363 - 18370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. L. Ebos, C. R. Lee, J. G. Christensen, A. J. Mutsaers, and R. S. Kerbel Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy PNAS, October 23, 2007; 104(43): 17069 - 17074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood, July 15, 2007; 110(2): 624 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Loupakis, A. Falcone, G. Masi, A. Fioravanti, R. S. Kerbel, M. Del Tacca, and G. Bocci Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity J. Clin. Oncol., May 1, 2007; 25(13): 1816 - 1818. [Full Text] [PDF]
|
|
|
|
|
|
A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al. Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor Clin. Cancer Res., May 1, 2007; 13(9): 2643 - 2650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Motzer, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, M. S. Ginsberg, S. T. Kim, C. M. Baum, S. E. DePrimo, et al. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., January 1, 2006; 24(1): 16 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, A. Onn, and A. Sandler Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications J. Clin. Oncol., May 10, 2005; 23(14): 3243 - 3256. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
